Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RKI983 vs Latanoprost in Glaucoma or Ocular Hypertension
NCT00846989Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rki983a in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Novartis. Started Jan 2009; status: completed.
02
Drugs
rki983a
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT00846989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846989.